EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus
developing, customizing, manufacturing, and marketing enzymes for the
chemical industry announced today that it has entered into a research
agreement with Bio Sidus, the leading biopharmaceutical company in
America
The agreement gives EUCODIS Bioscience exclusive access – for the search
of enzymes of interest – to Bio Sidus’ proprietary collection of
psychrophilic bacteria strains and other organisms isolated from the
Antarctic and the surrounding oceans. Psychrophiles are organisms that thrive
at low temperatures. EUCODIS Bioscience will use its experience in enzyme
development to screen the strains for enzymatic activities that can be used
in industrial and other commercial applications.
“We are excited that EUCODIS Bioscience gains access to Bio Sidus’
collection of psychrophilic microorganisms with their wealth of hitherto
untapped biological diversity,” commented
EUCODIS Bioscience.
“The biological diversity of organisms that are adapted to an extremely
cold environment offers a huge potential for the discovery and development of
novel enzymes. Enzymes that enable or accelerate chemical processes at a low
temperature offer tremendous commercial and environmental advantages for
energy-intensive industrial processes as well as for detergents and other
products for domestic applications.”
About EUCODIS Bioscience
EUCODIS Bioscience GmbH develops, optimizes, manufactures, and markets
industrial enzymes.
EUCODIS Bioscience’ products help customers in the chemical,
pharmaceutical, and food and feed industries to make manufacturing processes
more efficient and cleaner, and to generate products with superior properties.
EUCODIS Bioscience originally focused on developing enzymes for
industrial partners, including GlaxoSmithKline, Henkel, and Lohmann Animal
Health. Since 2009, the Company also markets its own products.
Led by an experienced management team, EUCODIS Bioscience is backed by
Austrian and German institutional venture capital funds, founders, and
private investors. The Company is headquartered in
subsidiaries in
For more information, please visit http://www.eucodisbioscience.com
About Bio Sidus
Bio Sidus is the leading biopharmaceutical company in
Sidus currently manufactures and markets human erythropoietin, human growth
hormone and human interferon Alfa 2a and 2b, amongst other proprietary
biotech developments. The company is part of Grupo Sidus, a leading developer
and manufacturer and pharmaceuticals, active pharmaceutical ingredients
(APIs) and biopharmaceuticals that are marketed in more than 90 countries.
Bio Sidus is based in
Company contact EUCODIS Bioscience:
Rudy Pandjaitan, PhD
CEO
EUCODIS Bioscience
Campus Vienna Biocenter II
Viehmarktgasse 2 a/ 2 OG
A-1030 Vienna
AUSTRIA
+43-1-8900804
office@eucodisbioscience.com
Media contact EUCODIS Bioscience:
Frank Butschbacher
Investor Relations & Communications
http://www.butschbacher.net
+43-650-7844940
office@butschbacher.net
SOURCE EUCODIS Bioscience